Ryutaro Shimazaki

710 total citations
20 papers, 466 citations indexed

About

Ryutaro Shimazaki is a scholar working on Nephrology, Genetics and Surgery. According to data from OpenAlex, Ryutaro Shimazaki has authored 20 papers receiving a total of 466 indexed citations (citations by other indexed papers that have themselves been cited), including 12 papers in Nephrology, 5 papers in Genetics and 4 papers in Surgery. Recurrent topics in Ryutaro Shimazaki's work include Parathyroid Disorders and Treatments (10 papers), Magnesium in Health and Disease (4 papers) and Genetic Syndromes and Imprinting (3 papers). Ryutaro Shimazaki is often cited by papers focused on Parathyroid Disorders and Treatments (10 papers), Magnesium in Health and Disease (4 papers) and Genetic Syndromes and Imprinting (3 papers). Ryutaro Shimazaki collaborates with scholars based in Japan, South Korea and United States. Ryutaro Shimazaki's co-authors include Masafumi Fukagawa, Tadao Akizawa, Hironori Kanda, Kengo Yamawaki, Kazuo Tamura, Seigo Nakamura, Yutaka Tokuda, Norikazu Masuda, Yoshinori Ito and Shigeatsu Endo and has published in prestigious journals such as PLoS ONE, Scientific Reports and Kidney International.

In The Last Decade

Ryutaro Shimazaki

20 papers receiving 461 citations

Peers

Ryutaro Shimazaki

NEPHR

ONCOL

GENET

SURGE

Rui Maio Portugal

Aurélien Mary France

Karin Shimada Japan

Claudia Fofi Italy

Paul Trevillian Australia

Ysamar Barrios Spain

Gary C.W. Chan Hong Kong

Jennifer A. Schaub United States

Panagiotis Giamalis Greece

Sara Gonçalves Portugal

Rui Maio Portugal

Ryutaro Shimazaki

58 ×0.3

NEPHR

124 ×0.8

ONCOL

67 ×0.6

GENET

190 ×2.8

SURGE

47 ×0.7

Citations per year, relative to Ryutaro Shimazaki Ryutaro Shimazaki (= 1×) peers Rui Maio

Countries citing papers authored by Ryutaro Shimazaki

Since Specialization

Citations

This map shows the geographic impact of Ryutaro Shimazaki's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Ryutaro Shimazaki with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Ryutaro Shimazaki more than expected).

Fields of papers citing papers by Ryutaro Shimazaki

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Ryutaro Shimazaki. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Ryutaro Shimazaki. The network helps show where Ryutaro Shimazaki may publish in the future.

Co-authorship network of co-authors of Ryutaro Shimazaki

This figure shows the co-authorship network connecting the top 25 collaborators of Ryutaro Shimazaki. A scholar is included among the top collaborators of Ryutaro Shimazaki based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Ryutaro Shimazaki. Ryutaro Shimazaki is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Shimazaki, Ryutaro & Kohji Kusano. (2021). Development of intranasal Sendai virus vector-based vaccine against COVID-19. 3(3). 122–124. 1 indexed citations

Tsuruya, Kazuhiko, Ryutaro Shimazaki, Masafumi Fukagawa, et al.. (2019). Efficacy and safety of evocalcet in Japanese peritoneal dialysis patients. Clinical and Experimental Nephrology. 23(6). 739–748. 11 indexed citations

Yokoyama, Keitaro, Ryutaro Shimazaki, Masafumi Fukagawa, et al.. (2019). Long-Term Efficacy and Safety of Evocalcet in Japanese Patients with Secondary Hyperparathyroidism Receiving Hemodialysis. Scientific Reports. 9(1). 6410–6410. 16 indexed citations

Yamawaki, Kengo, Hironori Kanda, & Ryutaro Shimazaki. (2018). Nrf2 activator for the treatment of kidney diseases. Toxicology and Applied Pharmacology. 360. 30–37. 55 indexed citations

Endo, Shigeatsu, et al.. (2018). An open-label, randomized, phase 3 study of the efficacy and safety of antithrombin gamma in patients with sepsis-induced disseminated intravascular coagulation syndrome. Journal of Intensive Care. 6(1). 75–75. 25 indexed citations

Shigematsu, Takashi, Ryutaro Shimazaki, Masafumi Fukagawa, & Tadao Akizawa. (2018). Pharmacokinetics of evocalcet in secondary hyperparathyroidism patients receiving hemodialysis: first-in-patient clinical trial in Japan. Clinical Pharmacology Advances and Applications. Volume 10. 101–111. 10 indexed citations

Akizawa, Tadao, et al.. (2018). Pharmacokinetics, Pharmacodynamics, and Safety of the Novel Calcimimetic Agent Evocalcet in Healthy Japanese Subjects: First-in-Human Phase I Study. Clinical Drug Investigation. 38(10). 945–954. 11 indexed citations

Fukagawa, Masafumi, Ryutaro Shimazaki, & Tadao Akizawa. (2018). Head-to-head comparison of the new calcimimetic agent evocalcet with cinacalcet in Japanese hemodialysis patients with secondary hyperparathyroidism. Kidney International. 94(4). 818–825. 59 indexed citations

Akizawa, Tadao, et al.. (2018). Phase 2b study of evocalcet (KHK7580), a novel calcimimetic, in Japanese patients with secondary hyperparathyroidism undergoing hemodialysis: A randomized, double-blind, placebo-controlled, dose-finding study. PLoS ONE. 13(10). e0204896–e0204896. 16 indexed citations

10.

Shigematsu, Takashi, et al.. (2018). Pharmacodynamics of evocalcet for secondary hyperparathyroidism in Japanese hemodialysis patients. Clinical and Experimental Nephrology. 23(2). 258–267. 9 indexed citations

11.

Cheong, Hae Il, Han‐Wook Yoo, Masanori Adachi, et al.. (2018). First‐in‐Asian Phase I Study of the Anti‐Fibroblast Growth Factor 23 Monoclonal Antibody, Burosumab: Safety and Pharmacodynamics in Adults With X‐linked Hypophosphatemia. JBMR Plus. 3(2). e10074–e10074. 10 indexed citations

12.

Maéda, Hiroshi, Masanari Shiramoto, Hiroaki Nakamura, et al.. (2018). Assessment of CYP‐Mediated Drug Interactions for Evocalcet, a New Calcimimetic Agent, Based on In Vitro Investigations and a Cocktail Study in Humans. Clinical and Translational Science. 12(1). 20–27. 9 indexed citations

13.

Kadowaki, Takashi, et al.. (2017). Efficacy and safety of saxagliptin in combination with insulin in Japanese patients with type 2 diabetes mellitus: a 16-week double-blind randomized controlled trial with a 36-week open-label extension. Expert Opinion on Pharmacotherapy. 18(18). 1903–1919. 7 indexed citations

14.

Matsushita, Kunihiro, Jingsha Chen, Yingying Sang, et al.. (2016). Risk of end-stage renal disease in Japanese patients with chronic kidney disease increases proportionately to decline in estimated glomerular filtration rate. Kidney International. 90(5). 1109–1114. 42 indexed citations

15.

Takeuchi, Yasuhiro, Shunsuke Takahashi, Daishu Miura, et al.. (2016). Cinacalcet hydrochloride relieves hypercalcemia in Japanese patients with parathyroid cancer and intractable primary hyperparathyroidism. Journal of Bone and Mineral Metabolism. 35(6). 616–622. 21 indexed citations

16.

Kubo, Kohmei, Yasuhiko Miyazaki, Tohru Murayama, et al.. (2016). A randomized, double‐blind trial of pegfilgrastim versus filgrastim for the management of neutropenia during CHASE(R) chemotherapy for malignant lymphoma. British Journal of Haematology. 174(4). 563–570. 35 indexed citations

17.

Kosaka, Yoshimasa, Yoshiaki Rai, Norikazu Masuda, et al.. (2015). Phase III placebo-controlled, double-blind, randomized trial of pegfilgrastim to reduce the risk of febrile neutropenia in breast cancer patients receiving docetaxel/cyclophosphamide chemotherapy. Supportive Care in Cancer. 23(4). 1137–1143. 73 indexed citations

18.

Masuda, Norikazu, Yutaka Tokuda, Seigo Nakamura, et al.. (2015). Dose response of pegfilgrastim in Japanese breast cancer patients receiving six cycles of docetaxel, doxorubicin, and cyclophosphamide therapy: a randomized controlled trial. Supportive Care in Cancer. 23(10). 2891–2898. 33 indexed citations

19.

Tsubakihara, Yoshiharu, Tadao Akizawa, Manabu Iwasaki, & Ryutaro Shimazaki. (2015). High Hemoglobin Levels Maintained by an Erythropoiesis‐Stimulating Agent Improve Renal Survival in Patients with Severe Renal Impairment. Therapeutic Apheresis and Dialysis. 19(5). 457–465. 14 indexed citations

20.

Jang, Jun Ho, Hironori Harada, Hirohiko Shibayama, et al.. (2015). A randomized controlled trial comparing darbepoetin alfa doses in red blood cell transfusion-dependent patients with low- or intermediate-1 risk myelodysplastic syndromes. International Journal of Hematology. 102(4). 401–412. 9 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact